Two Drugmakers Have Paused Autoimmune CAR T Cell Trials After Three Deaths from a Severe Immune Reaction
Novartis paused eight autoimmune CAR T trials after three severe immune reactions, and Bristol Myers Squibb paused enrollment in its program.
Medical Daily ·